RT Journal Article
SR Electronic
T1 Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.18.20197327
DO 10.1101/2020.09.18.20197327
A1 Rajasingham, Radha
A1 Bangdiwala, Ananta S
A1 Nicol, Melanie R
A1 Skipper, Caleb P
A1 Pastick, Katelyn A
A1 Axelrod, Margaret L
A1 Pullen, Matthew F
A1 Nascene, Alanna A
A1 Williams, Darlisha A
A1 Engen, Nicole W
A1 Okafor, Elizabeth C
A1 Rini, Brian I
A1 Mayer, Ingrid A
A1 McDonald, Emily G
A1 Lee, Todd C.
A1 Li, Peter
A1 MacKenzie, Lauren J
A1 Balko, Justin M
A1 Dunlop, Stephen J
A1 Hullsiek, Katherine H
A1 Boulware, David R
A1 Lofgren, Sarah M
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/09/21/2020.09.18.20197327.abstract
AB Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging virus causing the ongoing Covid-19 pandemic with no known effective prophylaxis. We investigated whether hydroxychloroquine could prevent SARS CoV-2 in healthcare workers at high-risk of exposure.Methods We conducted a randomized, double-blind, placebo-controlled clinical trial of healthcare workers with ongoing exposure to persons with Covid-19, including those working in emergency departments, intensive care units, Covid-19 hospital wards, and first responders.Participants across the United States and in the Canadian province of Manitoba were randomized to hydroxychloroquine 400mg once weekly or twice weekly for 12 weeks. The primary endpoint was confirmed or probable Covid-19-compatible illness. We measured hydroxychloroquine whole blood concentrations.Results We enrolled 1483 healthcare workers, of which 79% reported performing aerosol-generating procedures. The incidence of Covid-19 (laboratory-confirmed or symptomatic compatible illness) was 0.27 events per person-year with once-weekly and 0.28 events per person-year with twice-weekly hydroxychloroquine compared with 0.38 events per person-year with placebo. For once weekly hydroxychloroquine prophylaxis, the hazard ratio was 0.72 (95%CI 0.44 to 1.16; P=0.18) and for twice weekly was 0.74 (95%CI 0.46 to 1.19; P=0.22) as compared with placebo. Median hydroxychloroquine concentrations in whole blood were 98 ng/mL (IQR, 82-120) with once-weekly and 200 ng/mL (IQR, 159-258) with twice-weekly dosing. Hydroxychloroquine concentrations did not differ between participants who developed Covid-19 (154 ng/mL) versus participants without Covid-19 (133 ng/mL; P=0.08).Conclusions Pre-exposure prophylaxis with hydroxychloroquine once or twice weekly did not significantly reduce laboratory-confirmed Covid-19 or Covid-19-compatible illness among healthcare workers.Key Points In this randomized clinical trial of 1483 high-risk healthcare workers, there was no significant reduction in incidence of Covid-19 with once weekly or twice weekly hydroxychloroquine compared to placebo.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04328467Funding StatementThis work was supported by Jan and David Baszucki, Steve Kirsch, the Rainwater Charitable Foundation, the Alliance of Minnesota Chinese Organizations, the Minnesota Chinese Chamber of Commerce, and the University of Minnesota Foundation. Drs. Melanie Nicol, Radha Rajasingham, and Matthew Pullen are supported by the National Institute of Allergy and Infectious Disease (K08AI134262, K23AI138851, T32AI055433). Sarah Lofgren is supported by the National Institute of Mental Health (K23MH121220). Caleb Skipper is supported by a combined Fogarty International Center, National Institute of Neurological Disorders and Stroke grant (D43TW009345). Katelyn Pastick and Elizabeth Okafor were supported through the Doris Duke Charitable Foundation through a grant supporting the Doris Duke International Clinical Research Fellows Program at the University of Minnesota. Margaret Axelrod is supported by NIH T32GM007347 and F30CA236157. Drs. Lee and McDonald receive research salary support from the Fonds de recherche du Quebec Sante. In Manitoba research support was received from the Manitoba Medical Service Foundation and Research Manitoba. Rising Pharmaceuticals in the U.S. provided a donation of the hydroxychloroquine tablets. The REDCap software was supported by the National Institutes of Healths National Center for Advancing Translational Sciences, grant UL1TR002494. The funders had no role in trial design, trial implementation, writing of the manuscript, or the decision to submit it for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This trial was approved by the University of Minnesota Institutional Review Board, conducted under FDA Investigational New Drug (149252), and overseen by an independent DSMB. In Canada, the trial was authorized without objection by Health Canada (control number 238396), with ethics approval obtained from the University of Manitoba.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available 1 month after publication in a peer-reviewed journal. https://covidprep.umn.edu/